Cantor Fitzgerald Has Weak Estimate for EYPT FY2025 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of EyePoint Pharmaceuticals in a research note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings per share of ($3.15) for the year, down from their prior estimate of ($2.96). The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, hitting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $24.50 million for the quarter, compared to analyst estimates of $8.84 million.

A number of other research firms also recently commented on EYPT. StockNews.com upgraded EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, Chardan Capital dropped their price target on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $25.29.

EyePoint Pharmaceuticals Price Performance

EYPT stock traded down $0.42 on Monday, hitting $5.49. 907,138 shares of the company were exchanged, compared to its average volume of 820,840. The stock has a market capitalization of $377.77 million, a price-to-earnings ratio of -2.75 and a beta of 1.58. The business's fifty day moving average is $5.99 and its two-hundred day moving average is $7.45. EyePoint Pharmaceuticals has a twelve month low of $3.91 and a twelve month high of $13.99.

Institutional Trading of EyePoint Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC lifted its stake in shares of EyePoint Pharmaceuticals by 31.1% during the fourth quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company's stock worth $50,534,000 after purchasing an additional 1,607,268 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of EyePoint Pharmaceuticals by 51.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock valued at $42,838,000 after buying an additional 1,958,580 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of EyePoint Pharmaceuticals by 3.1% during the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company's stock valued at $30,825,000 after buying an additional 125,519 shares during the period. Federated Hermes Inc. lifted its position in EyePoint Pharmaceuticals by 10.2% during the 1st quarter. Federated Hermes Inc. now owns 4,085,580 shares of the company's stock worth $22,144,000 after acquiring an additional 378,135 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in EyePoint Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company's stock worth $20,782,000 after acquiring an additional 31,141 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.